Teva's Generic Wellbutrin XL For Major Depressive Disorder Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK has more than two years to market Wellbutrin XL in seasonal affective disorder before generics for that indication can launch.
You may also be interested in...
Teva’s Generic Bupropion XL Meets Bioequivalence To Wellbutrin XL, FDA Finds
Reported loss of antidepressant effect likely owed to natural disease progression, agency says.
Teva’s Generic Bupropion XL Meets Bioequivalence To Wellbutrin XL, FDA Finds
Reported loss of antidepressant effect likely owed to natural disease progression, agency says.
Biovail NDA For New Wellbutrin Formulation Is “Not Approvable”
FDA had concerns over design of pharmacokinetic studies of once-daily salt formulation of bupropion for depression, the firm says.